CN108341830B - 噻吩并嘧啶衍生物及其在药物中的应用 - Google Patents

噻吩并嘧啶衍生物及其在药物中的应用 Download PDF

Info

Publication number
CN108341830B
CN108341830B CN201810057305.4A CN201810057305A CN108341830B CN 108341830 B CN108341830 B CN 108341830B CN 201810057305 A CN201810057305 A CN 201810057305A CN 108341830 B CN108341830 B CN 108341830B
Authority
CN
China
Prior art keywords
methyl
methoxyphenyl
ethyl
oxy
deuterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810057305.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN108341830A (zh
Inventor
唐万军
杨新业
顾峥
李晨路
张宗远
万致富
王晓军
张英俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CN108341830A publication Critical patent/CN108341830A/zh
Application granted granted Critical
Publication of CN108341830B publication Critical patent/CN108341830B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201810057305.4A 2017-01-22 2018-01-22 噻吩并嘧啶衍生物及其在药物中的应用 Active CN108341830B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710052275 2017-01-22
CN2017100522753 2017-01-22

Publications (2)

Publication Number Publication Date
CN108341830A CN108341830A (zh) 2018-07-31
CN108341830B true CN108341830B (zh) 2021-03-02

Family

ID=62908330

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810057305.4A Active CN108341830B (zh) 2017-01-22 2018-01-22 噻吩并嘧啶衍生物及其在药物中的应用

Country Status (8)

Country Link
US (1) US10759812B2 (OSRAM)
EP (1) EP3571205B1 (OSRAM)
JP (1) JP7046959B2 (OSRAM)
KR (1) KR102577824B1 (OSRAM)
CN (1) CN108341830B (OSRAM)
AU (1) AU2018209006B2 (OSRAM)
CA (1) CA3049816A1 (OSRAM)
WO (1) WO2018133858A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI844474B (zh) 2016-03-02 2024-06-01 美商基利阿波羅有限責任公司 噻吩并嘧啶二酮acc抑制劑之固體型式及其製造方法
US10519165B2 (en) 2017-03-03 2019-12-31 Gilead Sciences, Inc. Processes for preparing ACC inhibitors and solid forms thereof
EP4424364A3 (en) 2017-03-28 2024-11-27 Gilead Sciences, Inc. Methods of treating liver disease
US11186587B2 (en) 2017-07-26 2021-11-30 Nanjing Sanhome Pharmaceutical Co., Ltd. Compound as ACC inhibitor and use thereof
EP3758706A4 (en) 2018-02-28 2021-11-24 The Regents Of The University Of Colorado WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THEREOF
CN109810085B (zh) * 2019-04-19 2019-07-19 上海皓元生物医药科技有限公司 Acc抑制剂及其中间体的制备方法
CN111848678A (zh) * 2019-04-30 2020-10-30 正大天晴药业集团股份有限公司 含磷类噻吩并嘧啶衍生物
EP3995498A4 (en) * 2019-07-02 2023-03-01 Sunshine Lake Pharma Co., Ltd. THIENOPYRIMIDINE DERIVATIVES HAVING STEREO CONFIGURATION AND THEIR USE IN MEDICINE
AR119594A1 (es) * 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
WO2022111517A1 (zh) * 2020-11-24 2022-06-02 正大天晴药业集团股份有限公司 氘修饰的噻吩并吡啶酮化合物
CN116745299A (zh) * 2021-02-07 2023-09-12 正大天晴药业集团股份有限公司 噻吩并嘧啶衍生物
CN117126174B (zh) * 2022-05-26 2025-12-05 广东东阳光药业股份有限公司 噻吩并嘧啶类化合物的共晶及其用途
CN117126175B (zh) * 2022-05-26 2025-12-05 广东东阳光药业股份有限公司 噻吩并嘧啶类化合物的共晶及其用途
TW202400151A (zh) * 2022-05-26 2024-01-01 大陸商廣東東陽光藥業股份有限公司 噻吩並嘧啶類化合物的晶型及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013071169A1 (en) * 2011-11-11 2013-05-16 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
WO2015007451A1 (en) * 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
WO2016112305A1 (en) * 2015-01-09 2016-07-14 Nimbus Apollo, Inc. Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19644228A1 (de) 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
US20070208040A1 (en) 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
AU2014262636A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
MX2015015421A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
US10208044B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
WO2015003881A1 (en) 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
EA201890949A1 (ru) 2015-11-25 2018-12-28 Джилид Аполло, Ллс СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
JP2019502660A (ja) 2015-11-25 2019-01-31 ギリアド アポロ， エルエルシー ピラゾールａｃｃ阻害剤およびその使用
EA201890910A1 (ru) 2015-11-25 2018-11-30 Джилид Аполло, Ллс ФУНГИЦИДНЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 2,4-ДИОКСО-1,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИНА
BR112018010453B1 (pt) 2015-11-25 2022-06-14 Gilead Apollo, Llc Compostos triazólicos inibindores de acetil coa carboxilase (acc)
WO2017147161A1 (en) 2016-02-23 2017-08-31 Raju Mohan Treatment of dermatological disorders or conditions
CN107698603B (zh) 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
WO2018171699A1 (zh) 2017-03-24 2018-09-27 浙江海正药业股份有限公司 氰基取代的杂芳基并嘧啶酮类衍生物及其制备方法和用途
WO2018171698A1 (zh) 2017-03-24 2018-09-27 浙江海正药业股份有限公司 杂芳基并嘧啶酮类衍生物及其制备方法和用途
WO2018228369A1 (zh) 2017-06-15 2018-12-20 浙江海正药业股份有限公司 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013071169A1 (en) * 2011-11-11 2013-05-16 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
WO2015007451A1 (en) * 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
WO2016112305A1 (en) * 2015-01-09 2016-07-14 Nimbus Apollo, Inc. Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Also Published As

Publication number Publication date
EP3571205A4 (en) 2020-06-03
AU2018209006B2 (en) 2021-04-22
CA3049816A1 (en) 2018-07-26
WO2018133858A1 (en) 2018-07-26
CN108341830A (zh) 2018-07-31
KR20190110575A (ko) 2019-09-30
JP2020505356A (ja) 2020-02-20
EP3571205B1 (en) 2023-08-30
KR102577824B1 (ko) 2023-09-13
EP3571205A1 (en) 2019-11-27
US20190352311A1 (en) 2019-11-21
JP7046959B2 (ja) 2022-04-04
US10759812B2 (en) 2020-09-01
AU2018209006A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
CN108341830B (zh) 噻吩并嘧啶衍生物及其在药物中的应用
KR102368298B1 (ko) 질소-함유 트라이사이클릭 화합물, 및 의약에서 이의 용도
CN110128432B (zh) 含氮三环化合物及其在药物中的应用
CN110770233B (zh) 稠合双环类化合物及其在药物中的应用
TWI878939B (zh) 五元並六元含氮化物、其中間體、製備方法和應用
CN111491920A (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
HK1209632A1 (en) Irak inhibitors and uses thereof
JP2021535141A (ja) αｖβ６インテグリンの阻害
CN108623615A (zh) 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
AU2014287471A1 (en) Fused piperidine amides as modulators of ion channels
KR20210125026A (ko) Tlr7 작용제로서의 이미다조[2,1-f][1,2,4]트리아진-4-아민 유도체
CN105399756B (zh) Btk抑制剂及其用途
CN113924303B (zh) 具有立体构型的噻吩并嘧啶衍生物及其在药物中的应用
KR20230124608A (ko) 무스카린성 아세틸콜린 수용체 m4의 길항제
WO2023237085A1 (zh) Hpk1抑制剂及其在医药上的应用
CN111303118B (zh) 化合物及其在治疗乙型肝炎中的用途
CN115043836A (zh) 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
CN115557913A (zh) 苯并氮杂环类化合物及其在药物中的应用
HK40011745A (en) Thienopyrimidine derivative and use thereof in medicine
HK40011745B (en) Thienopyrimidine derivative and use thereof in medicine
CN120569382A (zh) 三环类化合物及其制备方法和应用
CN119403801A (zh) Lrrk2抑制剂
WO2022148354A1 (zh) 多环类激酶抑制剂
TW202425971A (zh) 三環類化合物及其製備方法和應用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523000 Songshan Lake Science and Technology Industrial Park, Dongguan, Guangdong

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.

CP03 Change of name, title or address